ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BMYMP Bristol Myers Squibb Company (PK)

955.55
0.00 (0.00%)
09 Dec 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Bristol Myers Squibb Company (PK) USOTC:BMYMP OTCMarkets Preference Share
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 955.55 850.00 1,225.00 0.00 22:00:00

Form 8-K - Current report

15/02/2024 9:57pm

Edgar (US Regulatory)



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024


BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware
001-01136
22-0790350
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S Employer Identification No.)

Route 206 & Province Line Road,
Princeton, New Jersey 08543
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
BMY25
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024.  Mr. Holzer, 48, joined the Company in 2001. Most recently, from 2021 to 2024, he served as Senior Vice President, Finance, Treasury and Tax Operations. Prior to that, he served in multiple roles of increasing responsibility, including Senior Vice President, Enterprise Integrations from 2019 to 2021, Vice President and Head of Finance, Research & Development from 2018 to 2019, Chief Audit Officer from 2015 to 2018, and Vice President, U.S. Commercialization Finance from 2013 to 2015.  Mr. Holzer has a Bachelor of Science degree in Accounting from The University of Tampa and is a Certified Public Accountant.

Mr. Holzer is not a party to any arrangement or understanding regarding his selection as an officer. There are no family relationships between Mr. Holzer and any director or executive officer of the Company. Mr. Holzer is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit
No.
 
Description
     
104
 
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
 

EXHIBIT INDEX

Exhibit
No.
 
Description
   
104
 
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
 
       
Dated: February 15, 2024
By:
/s/ Kimberly M. Jablonski
 
 
Name:
Kimberly M. Jablonski
 
 
Title:
Corporate Secretary
 



v3.24.0.1
Document and Entity Information
Feb. 13, 2024
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2024
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE

1 Year Bristol Myers Squibb (PK) Chart

1 Year Bristol Myers Squibb (PK) Chart

1 Month Bristol Myers Squibb (PK) Chart

1 Month Bristol Myers Squibb (PK) Chart

Your Recent History

Delayed Upgrade Clock